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Abstract
Antithrombotic agents reduce risk of thromboembolism in severely ill patients.
Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits
from heparins. Optimal dosing and timing of these treatments and benefits of other
antithrombotic agents remain unclear. In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to
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develop recommendations on anticoagulants and antiplatelet agents for patients with
COVID-19 in different clinical settings. We used the American College of Cardiology
Foundation/American Heart Association methodology to assess level of evidence
(LOE) and class of recommendation (COR). Only recommendations with LOE A or B
were included. Panelists agreed on 12 recommendations: three for non-hospitalized,
five for non–critically ill hospitalized, three for critically ill hospitalized, and one for
post-discharge patients. Two recommendations were based on high-quality evidence,
the remainder on moderate-quality evidence. Among non–critically ill patients hospitalized for COVID-19, the panel gave a strong recommendation (a) for use of prophylactic dose of low molecular weight heparin or unfractionated heparin (LMWH/UFH)
(COR 1); (b) for select patients in this group, use of therapeutic dose LMWH/UFH in
preference to prophylactic dose (COR 1); but (c) against the addition of an antiplatelet agent (COR 3). Weak recommendations favored (a) sulodexide in non-hospitalized
patients, (b) adding an antiplatelet agent to prophylactic LMWH/UFH in select critically ill, and (c) prophylactic rivaroxaban for select patients after discharge (all COR
2b). Recommendations in this guideline are based on high-/moderate-quality evidence
available through March 2022. Focused updates will incorporate future evidence supporting changes to these recommendations.
KEYWORDS

anticoagulants, COVID-19, critical illness, platelet aggregation inhibitors
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I NTRO D U C TI O N

the pandemic may yield different results than earlier ones that are
synthesized in this guideline. Accordingly, planning for this guideline

Coronavirus disease 2019 (COVID-19) was declared a pandemic by the
1

included strategies to facilitate the rapid development of focused

World Health Organization on March 11, 2020. The pandemic has

updates as new evidence becomes available. The guideline focused

since progressed through several waves, each with distinct transmis-

on treatment questions for which high-quality evidence was avail-

sion and virulence characteristics that have been driven in large part

able; questions for which limited or low quality level of evidence

by the severe acute respiratory coronavirus 2 (SARS-CoV-2) variant,

was available are addressed in the accompanying ISTH COVID-19

the availability of COVID-19 testing, and the extent of vaccination cov-

Antithrombotic Good Practice Statements.4

erage in different populations. The pandemic continues to be fueled

The targeted audience for this guideline includes clinicians in in-

by reinfections, new variants, or subvariants of SARS-CoV-2 against

ternal medicine, intensive care, infectious disease, hematology, and

which vaccines are less effective, and waning immunity from previ-

vascular medicine, as well as hospitalists, family practitioners, and

ous vaccination and infection. In many countries vaccination rates are

other health-care providers who deliver inpatient or outpatient care

very low. Taken together, these ongoing challenges point to the urgent

to patients with COVID-19 or a COVID-19 diagnosis.

need for clinical practice guidelines that inform on evidence-based
management for COVID-19 patients in diverse clinical settings.
Numerous randomized controlled trials (RCTs) of various anti-

2
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thrombotic treatment regimens for patients with COVID-19 have
been conducted and published within a relatively short time span.

This guideline was developed using methods recommended by the

Based on this growing body of evidence, ISTH prioritized the transi-

American College of Cardiology Foundation and the American Heart

tion of its previously published guidance documents

2,3

into a formal

Association (ACCF/AHA).5,6

practice guideline using evidence from RCTs and well-designed observational studies with strong methodology.
To date, most RCTs and observational studies published have
recruited patients during the first waves with the initial variants of

2.1 | Panel selection and management of
conflicts of interest

SARS-CoV-2, and before vaccination was widely available. It is for
this reason that future studies of antithrombotic treatment among

ISTH empaneled 13 clinicians with outstanding knowledge of an-

patients with COVID-19 conducted during subsequent phases of

tithrombotic therapy as well as two patient representatives. The

|
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guideline chairman extended invitations to potential panelists, who

3. Established COVID-19 diagnosis

completed disclosures prior to being seated on the panel. Disclosures

4. Study designs: RCTs, prospective/retrospective cohort studies

included information on relationships with industry and other po-

5. Minimum follow-up: ≥7 days

tential conflicts of interest. Panelists were assigned to one of three

6. RCT minimum sample size ≥100

working groups that correspond to the patient categories and care

7. Observational study minimum sample size ≥400

3

settings covered in this guideline: critically ill patients, non–critically
ill patients, and outpatients (non-hospitalized and post-discharge).

Conflicts that arose during abstract review were adjudicated by

Critically ill and non–critically ill patients were defined based on cri-

the guideline methodologist. Once potentially relevant studies were

teria in each study. Please see evidence tables for more information

identified, full-text copies were provided to the appropriate work-

on these definitions. Although definitions for levels of illness will vary

ing group for review. Each working group then proposed a set of

among countries, health-care systems, stages of the COVID-19 pan-

included studies to the panel for discussion and approval. In some

demic, and so on, in general, patients not requiring mechanical venti-

cases, included papers were relevant to more than one recommen-

lation or organ support other than low-flow supplemental oxygen are

dation. Included papers and other guideline materials were main-

considered non–critically ill. Critical illness due to COVID-19 signi-

tained in shared, cloud-based files. Searches were rerun on March 6,

fies a life-threatening condition requiring immediate organ support,

2022 to ensure that all relevant studies were incorporated into the

such as invasive or non-invasive positive pressure ventilation, high-

recommendations immediately prior to submission for publication. A

flow supplemental oxygen therapy, vasopressor or inotrope support,

preprint of an RCT that was published on March 22, 2022 was avail-

extracorporeal membrane oxygenation, or continuous renal replace-

able to the panel and included in the evidence base for this guideline.

ment therapy, irrespective of patient location within a hospital.
The different dose levels of anticoagulants, that is, prophylactic,
intermediate, or therapeutic, are described in Table 1.

2.4 | Assessment of bias and the strength and
quality of evidence

2.2 | Search strategy and deployment

Evidence tables were developed for each recommendation with
data that described prespecified study characteristics and outcomes

With input from the guideline panel, an experienced medical librarian

from included studies (Appendix S1). These tables contain informa-

drafted search algorithms (PubMed, Cochrane, EMBASE) for each of

tion on potential biases for each included study, and panelists used

the 16 recommendations that were initially proposed for the guide-

this information in their assessment of available evidence for each

line (see Appendix S1 in supporting information). Searches were ex-

recommendation. In addition to assessing biases recommended by

ecuted in each database and de-duplicated files containing citations

Cochrane,8 additional potential biases related to the COVID-19 pan-

and abstracts were generated for each potential recommendation.

demic were examined. These included, for example, if institutional
anticoagulation protocols were introduced during a study's data collection period and when a study was conducted in relation to circu-

2.3 | Abstract review and identification of
included studies

lating COVID-19 variants and the availability of COVID-19 vaccine.
Panelists assessed the strength and quality of evidence for each
recommendation using ACCF/AHA methods (Figure 1).6 The class

Results files for each search were loaded into Abstrackr, an online
7

of recommendation (COR) indicates whether and to what degree

abstract review platform. Abstracts were screened by two review-

panelists determined that available evidence reflects benefits or

ers against a set of pre-specified criteria:

harms associated with a particular treatment; the level of evidence
(LOE) reflects panelists' assessment of the quality of the studies

1. Date range: January 1, 2020–December 17, 2021

that inform the recommendation, with RCTs providing higher qual-

2. Human subjects aged 18+

ity evidence than observational studies. This guideline focuses on

TA B L E 1 Dose levels of the anticoagulants used in the studies cited in the guideline
Drug

Prophylactic

Intermediate

Therapeutic

UFH

5000 U SQ BID or TID

7500 U SQ BID or TID

Intravenous, adjusted to APTT or anti-Xa

LMWH

Enoxaparin 40 mg SQ QD, dalteparin
5000 IU SQ QD, tinzaparin 4500 IU
SQ QD, bemiparin 3500 IU SQ QD

Enoxaparin 40 mg SQ BID or 80 mg SQ
QD, or 0.5 mg/kg SQ QD

Enoxaparin 1 mg/kg SQ BID, dalteparin
200 IU/kg SQ QD, tinzaparin 175 IU/kg
SQ QD, bemiparin 115 IU/kg SQ QD

DOAC

Rivaroxaban 10 mg PO QD, apixaban
2.5 mg PO BID

Not applicable

Rivaroxaban 20 mg PO QD, apixaban 5 mg
PO BID

Abbreviations: APTT, activated partial thromboplastin time; BID, twice daily; DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin;
PO, orally; QD, once daily; SQ, subcutaneous; TID, three times daily; UFH, unfractionated heparin.

4
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F I G U R E 1 Classification of recommendations and level of evidence. Reprinted with permission, Stroke.2021;52:e364-e 467 ©2021
American Heart Association, Inc.60
recommendations with LOE levels A and B. It presents three rec-

recommendation based on methods outlined by ACCF/AHA, includ-

ommendations for non-hospitalized patients with COVID-19; five

ing appropriate recusals. Repeat voting after revision aimed at reach-

recommendations for hospitalized, non–critically ill patients; three

ing consensus. Intellectual conflict of interest was not an exclusion

recommendations for hospitalized, critically ill patients; and one rec-

criterion for voting. Recommendations were approved by 93%–100%

ommendation for post-discharge patients.

of panel members, with 51% defined as the threshold for approval.
The panel met again to approve responses to the reviewers selected

2.5 | Debate and voting
Working groups drafted initial recommendations that were presented
to the full panel in a series of meetings in February and March 2022.

by the journal editor, to hold a final round of voting for these recommendations to ensure the guideline methodology remained robust.

2.6 | Public review and comment

Discussions were directed toward establishing consensus among
panelists and ensuring that the ACCF/AHA framework was applied

This document was posted on the website of ISTH and of other

uniformly for all recommendations. Voting was conducted for each

organizations for different stakeholders, including patients, for

|
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2 weeks during which public review and comment were invited. All

5

3.1.2 | Recommendation-specific supportive text

comments were reviewed by the guideline chairman and, if needed,
by the appropriate working group. Supportive text was amended as
required in response to the public comment period.

1. A placebo-controlled trial of non-hospitalized, non-pregnant patients with COVID-19 aged 40 to 80 at low risk of bleeding
who were randomized to 81 mg of aspirin daily or placebo

3

|

TR E ATM E NT R ECO M M E N DATI O N S

3.1 | Antithrombotic therapy for non-hospitalized
patients (Table 2)

showed lack of benefit for aspirin treatment.9 The composite
primary outcome included all-cause mortality, symptomatic
thrombosis, or hospitalization for cardiovascular or pulmonary
cause. The trial was terminated early due to low event rates
and small increases in both minor and clinically relevant non-
major bleeding (CRNMB)9,14 in the aspirin arm. A large cohort

3.1.1 | Synopsis

study of outpatients with COVID-19 compared those who were
prescribed aspirin for cardiovascular disease to those who

In this section of the guideline, the term “non-h ospitalized” refers

were not, and showed decreased risk of all-cause mortality

to adults with COVID-19 who reside in the community and have

both in- and out of the hospital among those on aspirin.15

no history of hospitalization for COVID-19. Studies that support

The study did not adjust for inpatient treatments, nor did it

recommendations in this section examined treatments that these

report bleeding events. Another population-based, outpatient

patients received in relation to outcomes such as subsequent

cohort study found a small increase in mortality among those

hospitalization and mortality. The traditional outcome in studies

on pre-existing anti-platelet therapy. However, there was no

on anticoagulants—venous or arterial thromboembolic events—is

adjustment for in-hospital treatments or adjustment for anti-

rare in non-h ospitalized patients.13 One RCT and two cohort stud-

thrombotic regimen modification.16 Although current data do

ies on antiplatelet agents and oral anticoagulants did not dem-

not support initiation of aspirin therapy among outpatients

onstrate any benefit of prescribing these agents after diagnosis

with COVID-19,9 there is also no clear evidence supporting

9–11

of COVID-19.

A single study that used a randomized control

design, showed that the glycosaminoglycan oral drug sulodexide

cessation of aspirin in outpatients with COVID-19 and a prior
cardiovascular indication for antiplatelet therapy.

may reduce risk of hospitalization and possibly also the need for

2. A placebo-controlled trial that randomized non-hospitalized, non-

oxygen supplementation.12 These results need to be confirmed in

pregnant patients with COVID-19 aged 40 to 80 at low risk of

future studies.

bleeding to 2.5 mg or 5 mg of apixaban twice daily showed lack
of benefit for both doses of apixaban.9 The composite primary
outcome included all-cause mortality, symptomatic thrombosis,

TA B L E 2 Recommendations for antithrombotic therapy for non-
hospitalized patients
COR

LOE

3: No Benefit

B-R

3: No Benefit

2b

B-R

B-R

or hospitalization for cardiovascular or pulmonary cause. The trial
was terminated early due to low event rates and small increases
in minor and CRNMB.14 A large cohort study of outpatients aged
65 and older showed that oral anticoagulation at the time of posi-

1. In non-hospitalized patients with
symptomatic COVID-19, initiation of
antiplatelet therapy is not effective to
reduce risk of hospitalization, arterial or
venous thrombosis, or mortality.9
2. In non-hospitalized patients with
symptomatic COVID-19, initiation
of direct oral anticoagulant (DOAC)
therapy is not effective to reduce risk
of hospitalization, arterial or venous
thrombosis, or mortality.9–11
3. In non-hospitalized patients with
COVID-19 at higher risk of disease
progression, initiation of oral sulodexide
therapy within 3 days of symptom onset
may be considered to reduce risk of
hospitalization.12

Note: Evidence from referenced studies that support recommendations
are summarized in Evidence Tables S10 and S11 in supporting
information.
Abbreviations: COR, class of recommendation; COVID-19, coronavirus
disease 2019; DOAC, direct oral anticoagulant; LOE, level of evidence.

tive SARS-CoV-2 test was associated with reduced mortality risk
or hospitalization among men.17 Two large cohort studies of outpatients with cardiovascular disease, who were mostly on direct
oral anticoagulants (DOACs), did not show reduced risk of hospitalization, death, or thrombosis.10,11 However, in the larger of
the two studies, no minimum exposure to outpatient oral anticoagulation was required, nor was there adjustment for in-hospital
treatments.10 A population-based outpatient cohort study found
a small increase in mortality risk among those on pre-existing
oral anticoagulation, but there was no adjustment for in-hospital
treatments or antithrombotic regimen modification.16Another
cohort study that evaluated a similar outpatient population demonstrated decreased hospitalization risk in the small subset of patients that was on anticoagulation for a cardiovascular indication
prior to hospitalization.18 Only one cohort study reported bleeding events, showing an infrequent, but statistically significantly
increased risk of bleeding in anticoagulated patients.10,11,16–18
Although current evidence does not support initiation of DOACs
among outpatients with COVID-19, there is also no evidence to

6
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support cessation of DOACs in outpatients with COVID-19 and a
prior cardiovascular indication for oral anticoagulation.18
3. In a single-center placebo-controlled trial, 243 non-hospitalized,
non-pregnant patients aged 40 and older with COVID-19 were

TA B L E 3 Recommendations for antithrombotic therapy for non–
critically ill, hospitalized patients
COR

LOE

1

B-NR

4. In non-critically ill patients hospitalized
for COVID-19, low (prophylactic) dose
LMWH or UFH is recommended in
preference to no LMWH or UFH to
reduce risk of thromboembolism and
possibly death. 20–26

1

A

5. In select non-critically ill patients
hospitalized for COVID-19, therapeutic-
dose LMWH or UFH is beneficial in
preference to low (prophylactic) or
intermediate dose LMWH or UFH to
reduce risk of thromboembolism and
end organ failure. 27–30

3: No Benefit

B-R

6. In non-critically ill patients hospitalized
for COVID-19, intermediate-dose
LMWH or UFH is not recommended
in preference to low (prophylactic)
dose LMWH or UFH to reduce risk of
thromboembolism and other adverse
outcomes. 20,31–34

3: Harm

A

7. In non-critically ill patients hospitalized
for COVID-19, add-on treatment with
an antiplatelet agent is potentially
harmful and should not be used.35,36

3: No Benefit

B-R

8. In non-critically ill patients hospitalized
for COVID-19, therapeutic-dose
DOAC is not effective to reduce risk of
thromboembolism and other adverse
outcomes.37

randomized to oral sulodexide 500 lipase-releasing units twice
daily or placebo.12 Sulodexide is a compound of two glycosaminoglycans, a fast-moving heparin fraction (80%) and dermatan sulfate (20%) that is used in parts of Europe, South America, and Asia
but does not have regulatory approval in other countries. Patients
were included in this trial if they were at higher risk of COVID-19
progression, as defined by the COVID-19 Health Complications
(C19HC) calculator, which takes age, body mass index, smoking
status, and chronic comorbidities into consideration.19 The study
medication was started within 3 days from onset of symptoms and
continued for 21 days. The trial showed a statistically significant
decrease in risk of hospitalization with an absolute risk reduction
(ARR) of 11.7%, a borderline significant reduction in oxygen supplementation, a non-significant decrease in all-cause mortality,
and no indication of harm associated with treatment. The trial did
not demonstrate decreased risk of thrombotic events. Overall,
the trial supports the effectiveness and safety of sulodexide in
12

outpatients with COVID-19.

3.2 | Antithrombotic therapy for non–critically ill,
hospitalized patients (Table 3)
3.2.1 | Synopsis
In this and the following section, data were examined for “non-
critically ill” and “critically ill” patients as defined by the selection
criteria in each included study (see “Study Characteristics” in the accompanying evidence tables). The variability across studies in these

Note: Evidence from referenced studies that support recommendations
are summarized in Evidence Tables S1–S5 in supporting information.
Abbreviations: COR, class of recommendation; COVID-19, coronavirus
disease 2019; DOAC, direct oral anticoagulant; LMWH, low molecular
weight heparin; LOE, level of evidence; UFH, unfractionated heparin.

definitions was considered by panelists during the evidence review.
Seven observational studies in non–critically ill patients hospitalized

3.2.2 | Recommendation-specific supportive text

for COVID-19 demonstrated reduced mortality risk with prophylactic dose low molecular weight heparin or unfractionated heparin
(LMWH/UFH) compared to no prophylaxis.

20–26

1. Seven observational studies revealed that among patients hos-

Despite these con-

pitalized for COVID-19, low (prophylactic) dose LMWH/UFH

sistent findings, the potential for bias and residual confounding in

compared to no LMWH/UFH reduced mortality by 24% to

observational studies led the panel to use the term “possibly” when

82%, 20,22–26,38 and one observational study showed an ARR of

describing reduced mortality risk in recommendation #4. None of the

11.4% in thromboembolic events or mortality with prophylactic

studies ascertained thromboembolism, but in view of the high risk

heparin over no anticoagulation.21 There was no significant

of thromboembolism in this population and a wealth of indirect data

increase in bleeding events in these studies. The risk of bias in

from well-designed trials, the panel recommended using these agents

these observational studies was generally low, with the possible

to reduce the thromboembolism risk. However, for patients with a low

exception for performance biases. Risk of venous thrombo-

risk of bleeding and with indicators—which varied across studies—of

embolism (VTE) in non–critically ill patients hospitalized for

increased risk of adverse events, therapeutic dose LMWH/UFH was

COVID-19 is approximately 3-fold higher overall than among

more effective than lower doses of LMWH/UFH to reduce the throm-

medically ill patients who were hospitalized in the pre-COVID

boembolism and end-organ failure risk.27–30 Conversely, intermediate

era with acute infection or pneumonia.21,39 Indirect evidence

dose LMWH/UFH,20,31–34 or therapeutic dose of a DOAC37 did not

from RCTs reveals that LMWH-based thromboprophylaxis is

appear to provide any benefit compared to prophylactic dose LMWH/

beneficial over no thromboprophylaxis in hospitalized medically

UFH, and addition of an antiplatelet agent to LMWH/UFH increased

ill patients, including those with acute infection.40,41 Due to

risk of major bleeding without any countervailing benefits.

35,36

acute infection, immobilization, respiratory failure, and elevated

|
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7

D-dimer, patients who are hospitalized for COVID-19 score

indications, good clinical practice suggests to continue DOAC

sufficiently high on commonly used risk assessment models,

therapy or, if clinically unstable, to be switched to a parenteral

to qualify as at a high risk for VTE and therefore to warrant

anticoagulant (LMWH or UFH).4

thromboprophylaxis.

42–4 4

2. Three randomized trials demonstrated benefits of therapeutic-
dose LMWH/UFH over low- to intermediate-dose heparins in
non–critically ill, non-pregnant patients hospitalized for COVID-

3.3 | Antithrombotic therapy for critically ill,
hospitalized patients (Table 4)

19.27–29 A large multiplatform trial (N = 2219) revealed an increase
in organ support–free days (days alive and free of intensive care
unit (ICU)-based respiratory or cardiovascular organ support),

29

Note that the recommendation does not apply to patients who otherwise have a clinical indication for therapeutic anticoagulation.

and another RCT revealed an ARR of 13.2% in major thromboembolism and mortality with therapeutic-dose LMWH or UFH

3.3.1 | Synopsis

over low-to intermediate-dose LMWH or UFH in non–critically ill
patient groups.28 A third RCT did not find a significant difference

For a description of the term “critically ill,” see the previous Synopsis.

in the primary outcome but revealed an ARR of 5.8% in all-cause

Use of prophylactic dose LMWH/UFH to prevent VTE in critically ill

mortality as a secondary outcome with therapeutic LMWH/

patients without active or high risk of bleeding is well established and

UFH over prophylactic LMWH/UFH.27 A meta-analysis of four

recommended.51,52 In the setting of COVID-19, available evidence

RCTs showed an ARR of 1.2% in major thromboembolism with

included only cohort studies with low-quality evidence for the com-

therapeutic LMWH/UFH over up to intermediate-dose LMWH/

parison of prophylactic dose LMWH/UFH versus control in critically

UFH without a statistically significant increase in major bleed-

ill patients. As a result, the panel refrained from making a recom-

ing.30 Patients with low bleed risk criteria were selected across

mendation regarding this regimen. Two RCTs in critically ill patients

trials, and selection criteria for two of the trials specified patients

hospitalized for COVID-19 failed to show any benefit of intermedi-

with elevated D-dimer and increased oxygen requirements.27,28

ate dose LMWH/UFH versus prophylactic dose.46,47 Two RCTs did

Therefore, in patients at low risk of bleeding and with risk factors

not show any benefit of therapeutic dose LMWH/UFH versus lower

for thromboembolism or organ failure, such as elevated D-dimer

doses to reduce mortality or need for organ support.28,48 In these

or increased oxygen requirements, therapeutic dose LMWH/UFH

trials, there were inconsistent results regarding reduction of throm-

should be considered.

boembolic events and a potential risk of increased major bleeding,

3. One small, randomized trial with important methodological limi-

despite exclusion of patients at high risk of bleeding, which led the

tations, including small sample size and a large number of proto-

panel to not recommend therapeutic dose of these agents. Addition

col violations, compared intermediate dose LMWH/UFH versus
standard dose LMWH/UFH in non–critically ill patients hospitalized for COVID-19 and showed no difference in need for mechanical ventilation or all-cause mortality.33 Four observational

TA B L E 4 Recommendations for antithrombotic therapy for
critically ill, hospitalized patients

studies yielded inconsistent results concerning the benefits of

COR

LOE

intermediate dose LMWH/UFH over low (prophylactic) dose

3: No Benefit

B-R

9. In critically ill patients hospitalized for
COVID-19, intermediate dose LMWH/UFH
is not recommended over prophylactic
dose LMWH/UFH to reduce risk of
adverse events, including mortality and
thromboembolism.45–47

3: No Benefit

B-R

10. In critically ill patients hospitalized for
COVID-19, therapeutic dose LMWH/UFH
is not recommended over usual-c are or
prophylactic dose LMWH/UFHs. 28,48,49*

2b

B-R

11. In select critically ill patients hospitalized
for COVID-19, add on treatment with an
antiplatelet agent to prophylactic dose
LMWH/UFH is not well established
but might be considered to reduce
mortality.36,50

LMWH/UFH.

20,31,32,34

4. Two RCTs (including the large RECOVERY trial, N = 14 892)36 revealed no mortality benefit of antiplatelet therapy (including aspirin and P2Y12 inhibitors) as add-on therapy among non–critically
ill patients hospitalized for COVID-19.35,36 These trials also indicated evidence of harm with increased major bleeding events
in patients on antiplatelet therapy. In one trial the use of study
antiplatelet therapy was given on top of therapeutic-dose heparin.35,36 However, among patients who are already on antiplatelet therapy with clear indications, good clinical practice suggests
continuation of antiplatelet therapy if a patient is hospitalized for
COVID-19.4
(One panel member voted for COR 3: No Benefit.)
5. One moderate-size RCT of patients hospitalized for COVID-19
showed no benefit of the DOAC rivaroxaban at a therapeutic dose,
20 mg daily, neither during hospitalization nor post-discharge,
over inpatient low (prophylactic) dose LMWH or UFH.37 For patients hospitalized for COVID-19 and already on a DOAC for clear

Note: Evidence from referenced studies that support recommendations
are summarized in Evidence Tables S7, S8 and S9b in supporting
information.
Abbreviations: COR, class of recommendation; COVID-19, coronavirus
disease 2019; DOAC, direct oral anticoagulant; LMWH, low molecular
weight heparin; LOE, level of evidence; UFH, unfractionated heparin.
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of an antiplatelet agent to treatment with LMWH/UFH was exam-

3. In a large RCT (REMAP-CAP; N = 1549) critically ill patients hos-

ined in one RCT that included both non–critically and critically ill

pitalized for COVID-19 received aspirin 75–100 mg daily, a P2Y12

patients. In this trial, the combined regimen was not effective in re-

inhibitor (mainly clopidogrel at 75 mg daily without loading dose),

ducing mortality in either subgroup and there was increased risk of

or no antiplatelet therapy.50 Most patients (90%) also received

bleeding events.

36

In another RCT, addition of an antiplatelet agent

LMWH, and 72% of VTE prophylaxis was at low (prophylactic) or

to prophylactic dose LMWH/UFH reduced mortality until discharge.

intermediate dose. The trial was stopped for futility to demonstrate

Reduced mortality had reached even higher probability by day 90,

a difference in the primary outcome, which was organ support–free

but this benefit was accompanied by increased risk of bleeding.50 Key

days. Because results from the two antiplatelet groups were similar,

differences in design between the two trials, as described below (sup-

they were pooled and compared to control. The adjusted absolute

portive text for Recommendation 11) may explain the inconsistent

difference between groups in survival until discharge was 5% (95%

results concerning the role of antiplatelet agents in mortality risk.

confidence interval, −0.2, 9.5) with 97% posterior probability of efficacy with antiplatelet therapy. The adjusted absolute difference
in survival until 90 days was also 5% with 99.7% posterior probabil-

3.3.2 | Recommendation-specific supportive text

ity of efficacy with antiplatelet therapy. However, the risk of major
bleeding50,54 increased with antiplatelet therapy, with an adjusted

1. Two RCTs comparing intermediate versus low (prophylactic)

absolute risk increase of 0.8% with 99.4% probability of harm. Post

dose LMWH/UFH in critically ill adults were identified.45–47

hoc analyses indicated increased risk of bleeding when antiplate-

In one trial (INSPIRATION; N = 562) results were available

let therapy was combined with therapeutic dose anticoagulation.

in two publications: one reporting on 30 days of follow-up,47

A very large RCT (RECOVERY), randomized 14 892 adults with

and the other on 90 days.45 The primary outcome, which was

COVID-19 to aspirin 150 mg daily or usual care.36 Among patients

a composite of venous or arterial thrombosis, treatment with

receiving non-invasive or invasive ventilation (N = 4920) there was

extracorporeal membrane oxygenation, and all-cause mortality,

no reduction in mortality risk at 28 days with aspirin compared to

did not differ across treatment arms, a null finding similar to

control. It is important to note that in the REMAP-CAP trial, diver-

other outcomes that were assessed in this trial. In the second

gence in cumulative mortality risk occurred between day 28 and

RCT (N = 176) prophylactic versus intermediate-dose LMWH

day 90, aspirin dose was lower than in the RECOVERY trial, and

were compared in patients admitted to the ICU and/or showed

risk of bleeding was likely mitigated by enrolling patients at low risk

laboratory evidence of coagulopathy.46 The primary outcome,

of bleeding and by recommending gastric acid suppression.50 The

30-day all-cause mortality, was 15% in the intermediate and

combination of antiplatelet agents with therapeutic dose anticoag-

21% in the prophylactic LMWH dose groups, a difference that

ulation is probably harmful in critically ill patients with COVID-19.

was not statistically significant. Neither trial showed differences
in venous or arterial event rates or major bleeding.
2. A large multiplatform RCT (N = 1098) in critically ill patients hospitalized for COVID-19 was halted for futility to demonstrate a

3.4 | Antithrombotic therapy for patients
discharged from hospital (Table 5)

difference in the primary outcome of organ support-free days
between therapeutic dose of LMWH/UFH and lower doses of

3.4.1 | Synopsis

LMWH/UFH.48 However, the trial showed a 4% ARR in major
thromboembolic events without significant differences in ei-

Patients with COVID-19, who survive until discharge from the hos-

ther mortality or major bleeding in the therapeutic LMWH/UFH

pital, may still be at increased risk of adverse outcomes. Some pa-

group versus usual care thromboprophylaxis. Another RCT that

tients demonstrate biomarkers for residual hypercoagulability (high

included 83 critically ill patients hospitalized for COVID-19 did

D-dimer),55 and elevated inflammatory response (high C-reactive

not show significant differences in any outcomes between therapeutic dose of LMWH/UFH and lower doses of LMWH/UFH.28
A meta-analysis of three RCTs28,48,53 demonstrated among the

TA B L E 5 Recommendation for patients discharged from hospital

critically ill patients a significant reduction in major thrombotic

COR

LOE

events (ARR 4.1%) with therapeutic dose LMWH/UFH, as well

2b

B-R

as a non-significant increase in risk of major bleeding and a decrease in organ support–free days.30 However, the weighted
results of the meta-analysis are dominated by findings from the
multiplatform RCT.48 Although these results do not support escalation of LMWH/UFH to therapeutic dose, patients with a clear
indication—new or recent VTE, atrial fibrillation, mechanical heart
valves—should be offered therapeutic dose LMWH/UFH unless
contraindicated.

12. In select patients who have been
hospitalized for COVID-19, post-discharge
treatment with prophylactic dose
rivaroxaban for approximately 30 days
may be considered to reduce risk of
VTE.55,56

Note: Evidence from referenced studies that support recommendations
are summarized in Evidence Table S14 in supporting information.
Abbreviations: COR, class of recommendation; COVID-19, coronavirus
disease 2019; LOE, level of evidence; VTE, venous thromboembolism.
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protein),57 which might increase post-discharge risk of thromboem-

These findings are supported by results from a registry on pa-

bolic events and death in the convalescence. One RCT showed that

tients post–COVID-19 hospital discharge early on in the pan-

prophylactic dose of a DOAC (rivaroxaban) compared to no antico-

demic.55 Therefore, in patients with persistent risk factors for

agulation reduced risk of non-fatal or fatal VTE without a significant

VTE that may include an IMPROVE score of ≥4 or 2–3 with a

increase in bleeding risk.56 Data from a large registry study sup-

D-dimer above the upper limit of normal, and without contrain-

ported findings from this trial.

55

dication (e.g., high risk of bleeding, pregnancy, lactation), post-
discharge treatment with 10 mg of rivaroxaban daily may be
considered. Results from studies with other DOACs are not yet

3.4.2 | Recommendation-specific supportive text
1. In an open-label, multicenter RCT of non-pregnant adults with
increased risk of thrombosis, who were hospitalized for a mini-

available. (One panel member voted for COR 2a.)

4

|

DISCUSSION

mum of 3 days for COVID-19, post-discharge treatment with
rivaroxaban 10 mg per day for 35 days was compared to no

The guideline panel identified during the project new published

anticoagulation.56 Increased risk of thrombosis was defined as

data that potentially could generate additional recommendations

an elevated modified International Medical Prevention Registry

(Evidence Tables S9b and S11b) in supporting information. The

on Venous Thromboembolism (IMPROVE) VTE-score of 2–3 with

first one concerned the question whether treatment with an anti-

D-dimer level more than two times the upper limit of normal

platelet agent in critically ill patients with COVID 19 is beneficial,

at discharge or an IMPROVE VTE score of 4 or greater irre-

which yielded Recommendation 11. The second question was re-

spective of the D-dimer level at discharge.58 Enrolled patients

lated to the original question whether oral anticoagulants in non-

had bilateral lower limb venous Doppler ultrasound and computed

hospitalized patients with COVID-19 is beneficial but specifically

tomography pulmonary angiograms performed on day 35 post-

addressing DOACs versus vitamin K antagonists. This was prompted

randomization. Rivaroxaban 10 mg daily was associated with

by the identification in the first literature search of a retrospective

decreased risk of symptomatic or fatal VTE, but there was no

cohort study with more than 300 000 patients.59 The study showed

difference in risk of death or arterial thrombosis. Results showed

a significant reduction in mortality among patients on warfarin com-

14,54

pared to DOACs. Due to potential risk of selection bias, performance

low risk of CRNMB and no increased risk of major bleeding.

F I G U R E 2 Summary of the recommendations. Color coding refers to the COR. For further details, see Recommendation-specific
supportive texts and evidence tables (in the Appendix S1). COR, class of recommendation; DOAC, direct oral anticoagulant; LMWH, low
molecular weight heparin; LOE, level of evidence; UFH, unfractionated heparin.
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S U P P O R T I N G I N FO R M AT I O N
Additional supporting information can be found online in the
Supporting Information section at the end of this article.
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